| Bioactivity | (S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1[1]. | ||||||||||||
| Invitro | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein.PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins. | ||||||||||||
| Name | (S,R,S)-AHPC-C8-NH2 | ||||||||||||
| CAS | 2341796-79-8 | ||||||||||||
| Formula | C31H47N5O4S | ||||||||||||
| Molar Mass | 585.80 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Jian Jin, et al. Serine threonine kinase (akt) degradation / disruption compounds and methods of use. Patent WO2019173516A1. |
(S,R,S)-AHPC-C8-NH2
CAS: 2341796-79-8 F: C31H47N5O4S W: 585.80
(S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 base
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.